p16 upregulation is linked to poor prognosis in ERG negative prostate cancer

[1]  W. Feng,et al.  Association of p16 gene methylation with prostate cancer risk: a meta-analysis. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[2]  G. Sauter,et al.  Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers , 2015, PloS one.

[3]  G. Sauter,et al.  The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG‐negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression , 2014, International journal of cancer.

[4]  H. Fu,et al.  Androgen Receptor Accelerates Premature Senescence of Human Dermal Papilla Cells in Association with DNA Damage , 2013, PloS one.

[5]  Anirban P. Mitra,et al.  A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy , 2013, Prostate Cancer and Prostatic Disease.

[6]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[7]  S. Kurtz,et al.  Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.

[8]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[9]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[10]  G. Sauter,et al.  Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers , 2013, International journal of cancer.

[11]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[12]  M. Heckman,et al.  Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer , 2012, The Prostate.

[13]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[14]  I. Thompson,et al.  Prostate cancer--uncertainty and a way forward. , 2012, The New England journal of medicine.

[15]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[16]  M. Rubin,et al.  Oncogene-mediated alterations in chromatin conformation , 2012, Proceedings of the National Academy of Sciences.

[17]  Bruce J Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[18]  Jing Shen,et al.  DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. , 2012, DNA and cell biology.

[19]  P. Vlachostergios,et al.  Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer , 2012, Journal of Negative Results in BioMedicine.

[20]  Tim Beißbarth,et al.  TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.

[21]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[22]  Ming-Daw Tsai,et al.  Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. , 2011, Biochemistry.

[23]  M. Eccles,et al.  PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein , 2011, Oncogene.

[24]  A. Mazo,et al.  p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors , 2011, Oncogene.

[25]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[26]  A. Haese*,et al.  High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.

[27]  Hartwig Huland,et al.  Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.

[28]  B. Han.  ETS Gene Fusions in Prostate Cancer , 2009 .

[29]  M. von Knebel Doeberitz,et al.  p16 methylation does not affect protein expression in cervical carcinogenesis. , 2008, European journal of cancer.

[30]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[31]  D. Grignon,et al.  Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[33]  M. Hoque,et al.  A Quantitative Promoter Methylation Profile of Prostate Cancer , 2004, Clinical Cancer Research.

[34]  Ronald Simon,et al.  Tissue microarrays for early target evaluation. , 2004, Drug discovery today. Technologies.

[35]  P. Okunieff,et al.  Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Heisey,et al.  Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. , 2002, Cancer letters.

[37]  G. Peters,et al.  Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence , 2001, Nature.

[38]  C. Cordon-Cardo,et al.  Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. , 1999, Journal of the National Cancer Institute.

[39]  C. Cordon-Cardo,et al.  Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[41]  M. Tsai,et al.  Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. , 1997, Cancer research.

[42]  O. Halvorsen,et al.  Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. , 1997, Urologic oncology.

[43]  B. Verdoodt,et al.  ORIGINAL ARTICLE Inverse association of p16 INK4a and p14 ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer , 2011 .

[44]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[45]  Ronald Simon,et al.  Immunohistochemical analysis of tissue microarrays. , 2010, Methods in molecular biology.

[46]  Ronald Simon,et al.  Tissue Microarrays , 2010, Methods in Molecular Biology.

[47]  O. Halvorsen,et al.  Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. , 2000, Cancer.

[48]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.